|
1
|
Wild S, Roglic G, Green A, Sicree R and
King H: Global prevalence of diabetes: Estimates for the year 2000
and projections for 2030. Diabetes Care. 27:1047–1053. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mehuys E, De Bolle L, Van Bortel L,
Annemans L, Van Tongelen I, Remon JP and Giri M: Medication use and
disease management of type 2 diabetes in Belgium. Pharm World Sci.
30:51–56. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Studholme S: Diabetic retinopathy. J
Perioper Pract. 18:205–210. 2008.PubMed/NCBI
|
|
4
|
Lee K, Ahn JM, Kim EK and Kim TI:
Comparison of optical quality parameters and ocular aberrations
after wavefront-guided laser in-situ keratomileusis versus
wavefront-guided laser epithelial keratomileusis for myopia.
Graefes Arch Clin Exp Ophthalmol. 251:2163–2169. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yan SF, D'Agati V, Schmidt AM and Ramasamy
R: Receptor for advanced glycation endproducts (RAGE): A formidable
force in the pathogenesis of the cardiovascular complications of
diabetes and aging. Curr Mol Med. 7:699–710. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bierhaus A, Hofmann MA, Ziegler R and
Nawroth PP: AGEs and their interaction with AGE-receptors in
vascular disease and diabetes mellitus. I. The AGE concept.
Cardiovasc Res. 37:586–600. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Singh R, Barden A, Mori T and Beilin L:
Advanced glycation end-products: A review. Diabetologia.
44:129–146. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Adamis AP: Is diabetic retinopathy an
inflammatory disease? Br J Ophthalmol. 86:363–365. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Seiler T, Kaemmerer M, Mierdel P and
Krinke HE: Ocular optical aberrations after photorefractive
keratectomy for myopia and myopic astigmatism. Arch Ophthalmol.
118:17–21. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jubb AM, Bell SM and Quirke P: Methylation
and colorectal cancer. J Pathol. 195:111–134. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lam DW and LeRoith D: The worldwide
diabetes epidemic. Curr Opin Endocrinol Diabetes Obes. 19:93–96.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Schmidt AM, Vianna M, Gerlach M, Brett J,
Ryan J, Kao J, Esposito C, Hegarty H, Hurley W, Clauss M, et al:
Isolation and characterization of two binding proteins for advanced
glycosylation end products from bovine lung which are present on
the endothelial cell surface. J Biol Chem. 267:14987–14997.
1992.PubMed/NCBI
|
|
13
|
Logsdon CD, Fuentes MK, Huang EH and
Arumugam T: RAGE and RAGE ligands in cancer. Curr Mol Med.
7:777–789. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yan SF, Ramasamy R and Schmidt AM:
Mechanisms of disease: Advanced glycation end-products and their
receptor in inflammation and diabetes complications. Nat Clin Pract
Endocrinol Metab. 4:285–293. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Carey AL, Lamont B, Andrikopoulos S,
Koukoulas I, Proietto J and Febbraio MA: Interleukin-6 gene
expression is increased in insulin-resistant rat skeletal muscle
following insulin stimulation. Biochem Biophys Res Commun.
302:837–840. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Aljada A, Garg R, Ghanim H, Mohanty P,
Hamouda W, Assian E and Dandona P: Nuclear factor-kappaB
suppressive and inhibitor-kappaB stimulatory effects of
troglitazone in obese patients with type 2 diabetes: Evidence of an
antiinflammatory action? J Clin Endocrinol Metab. 86:3250–3256.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
André-Schmutz I, Hindelang C, Benoist C
and Mathis D: Cellular and molecular changes accompanying the
progression from insulitis to diabetes. Eur J Immunol. 29:245–255.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Krylova IN, Sablin EP, Moore J, Xu RX,
Waitt GM, MacKay JA, Juzumiene D, Bynum JM, Madauss K, Montana V,
et al: Structural analyses reveal phosphatidyl inositols as ligands
for the NR5 orphan receptors SF-1 and LRH-1. Cell. 120:343–355.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ben-Mahmud BM, Chan WH, Abdulahad RM,
Datti A, Orlacchio A, Kohner EM and Chibber R: Clinical validation
of a link between TNF-α and the glycosylation enzyme core 2
GlcNAc-T and the relationship of this link to diabetic retinopathy.
Diabetologia. 49:2185–2191. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yamamoto Y, Kato I, Doi T, Yonekura H,
Ohashi S, Takeuchi M, Watanabe T, Yamagishi S, Sakurai S, Takasawa
S, et al: Development and prevention of advanced diabetic
nephropathy in RAGE-overexpressing mice. J Clin Invest.
108:261–268. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yamagishi S, Nakamura K, Matsui T, Noda Y
and Imaizumi T: Receptor for advanced glycation end products
(RAGE): A novel therapeutic target for diabetic vascular
complication. Curr Pharm Des. 14:487–495. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Reiniger N, Lau K, McCalla D, Eby B, Cheng
B, Lu Y, Qu W, Quadri N, Ananthakrishnan R, Furmansky M, et al:
Deletion of the receptor for advanced glycation end products
reduces glomerulosclerosis and preserves renal function in the
diabetic OVE26 mouse. Diabetes. 59:2043–2054. 2010. View Article : Google Scholar : PubMed/NCBI
|
